Agenus up-to-$340 m private placement, to fund operations through end of 2031

 

Agenus announces up-to-$340 million private placement, expects financing to fund operations through end of 2031

• Private placement was oversubscribed, indicating strong investor demand for Agenus financing of up to $340 million.
• Agenus plans to use private placement proceeds to fund its ROBBIN trial in MSS colon cancer.
• Agenus will discontinue financial support for its BATTMAN Phase 3 MSS colorectal cancer study.
• Company expects full operational funding through 2031 only if all associated private placement warrants are exercised.

https://finviz.com/stock?t=AGEN&p=d